The cancer patient with severe mucositis.
Oropharyngeal mucositis is a painful, often dose-limiting side effect of both radiotherapy and chemotherapy. To reduce the intensity of pain and prevent systemic infection via the compromised mucosa, agents such as antiseptic mouthwashes, anti-ulcer compounds, sodium bicarbonate, saline, and allopurinol have been traditionally used with limited success. The new agents that show promise are granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). However, best results, dosage, and means of administration still have to be determined. Other agents such as sucralfate, tretinoin, glutamine, and misoprostol are also being tested. The results reported from different testing centers are often contradictory and confusing. Basic requirements in prevention and control of mucositis are good oral hygiene, mechanical débridement of the oral tissues, and hydration.
Carl
W
W
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Havens
J
J
D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D009059:Mouth Diseases / Q000175:diagnosis / Q000209:etiology*; D009061:Mouth Mucosa / Q000528:radiation effects*; D010146:Pain / Q000175:diagnosis / Q000209:etiology*; D059408:Pain Management; D010147:Pain Measurement; D011878:Radiotherapy / Q000009:adverse effects*; D012720:Severity of Illness Index
D016178:Granulocyte-Macrophage Colony-Stimulating Factor